期刊文献+

叶酸修饰纳米载体抑制P糖蛋白改善肿瘤耐药的研究进展 被引量:3

Research progress of folate functionalized nanoparticles in diverting P-glycoprotein mediated drug efflux
原文传递
导出
摘要 化疗仍然是许多肿瘤患者的主要治疗手段。但是,P糖蛋白(P-gp)介导的多药耐药对化疗提出了严峻的挑战。靶向纳米载体的运用使抑制或绕过P-gp成为可能。叶酸受体在肿瘤组织中表达量高,且叶酸具有稳定性好、无毒性及免疫原性等优势,使得叶酸在纳米载体的修饰中被广泛应用。文章就叶酸修饰的靶向纳米药物载体在抑制P-gp中的应用进行综述。 Chemotherapy remains the main treatment for many cancer patients. However, P-glycoprotein (P-gp) mediated multidrug resistance poses severe challenges to current chemotherapies. As ideal vectors to overcome drug resistance, nanovehicles are extensively explored for cancer treatment by diverting P-gp mediated drug efflux mechanisms. Surface engineering of nanocarriers has attracted great attention for targeted therapeutic delivery. The folate receptors, one of the most researched targets in cancer therapeutics, are over-expressed in several carcinomas. And folate has become one of the most investigated ligands in cancer therapeutic direction due to its small size, easy conjugation to nanocarriers, nontoxic, nonimmunogenic nature, and well stability in storage or in circulation. This review discussed the current status of folate functionalized nanoparticles in diverting P-gp mediated drug efflux mechanisms.
出处 《肿瘤研究与临床》 CAS 2015年第7期502-504,共3页 Cancer Research and Clinic
关键词 肿瘤耐药 P糖蛋白 纳米载体 叶酸 Tumor multidrug resistance P-glycoprotein Nanoparticles Folate
  • 相关文献

参考文献22

  • 1Wn Q, Yang Z, Nie Y, et al. Multi-drug resistance in cancer chemotherapeutics: mechanisms and lab approaches [ J ]. Cancer Lett, 2014, 347(2) : 159-166.
  • 2Silva R, Vilas-Boas V, Carmo H, et al. Modulation of P-glycoprotein efflux pump : induction and activation as a therapeutic strategy [ J ]. Pharmacol Ther, 2015, 149: 1-123.
  • 3Kapse-Mistry S, Govender T, Srivastava R, et al. Nanodrug delivery in reversing multidrug resistance in cancer cells [ J ]. Front Pharmacol, 2014,5 : 159.
  • 4胡文庆,闫曙光,王泽华,彭春伟,周英,李雁.胃癌中P-糖蛋白、多药耐药相关蛋白、肺耐药蛋白的表达及其意义[J].肿瘤研究与临床,2010,22(4):247-249. 被引量:5
  • 5Zinzi L, Capparelli E, Cantore M, et al. Small and innovative molecules as new strategy to revert MDR [ J ]. Front Oncol, 2014, 4: 2.
  • 6Pajeva IK, Sterz K, Christlieb M, et al. Interactions of the muhidrug resistance modulators tariquidar and elacridar and their analogues with P-glycoprotein [ J ]. Chem Med Chem, 2013, 8 ( 10 ) : 1701- 1713.
  • 7Loo TW, Clarke DM. Tariquidar inhibits P-glycoprotein drug efflux but activates ATPase activity by blocking transition to an open conformation [ J ]. Biochem Pharmacol, 2014, 92 ( 4 ) : 558-566.
  • 8Kelly R J, Draper D, Chen CC, et al. A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar ( XR9576 ) in patients with lung, ovarian, and cervical cancer [ J ]. Clin Cancer Res, 2011, 17 ( 3 ) : 569-580.
  • 9Sheng L, Xiong M, Li C, et al. Reversing muhidrug-resistant by RNA interfence through silencing MDR1 gene in human hepatocellular carcinoma cells subline Bel-7402 / ADM [ J ]. Pathol Oncol Res, 2014, 20( 3 ): 541-548.
  • 10Yin Q, Shen J, Chen L, et al. Overcoming multidrug resistance by o-delivery of Mdr-1 and survivin-targeting RNA with reduction- responsible cationic poly ( beta-amino esters ) [ J ]. Biomaterials, 2012, 33 ( 27 ) : 6495-6506.

二级参考文献15

  • 1赵晓红,翟惠虹,白冬利,韩恩善,胡建国,郭新宁.化疗前、后胃癌组织中P-糖蛋白的表达[J].宁夏医学杂志,2004,26(12):794-795. 被引量:1
  • 2张爱民,胡佑伦.胃癌耐药基因的表达及其在药物适配个体化治疗中的意义[J].中华实验外科杂志,2004,21(12):1485-1487. 被引量:10
  • 3许洪伟,丛衍群,王万忠,姜军梅,秦成坤,秦成勇.P-糖蛋白、多药耐药相关蛋白在胃癌的表达与化疗敏感性的相关性研究[J].山东大学学报(医学版),2005,43(7):594-597. 被引量:9
  • 4高福莲,马开颜,张钦宪.P-gp、MRP、LRP、GSTπ和TOPOII在胃癌表达的趋势[J].胃肠病学和肝病学杂志,2006,15(2):216-218. 被引量:8
  • 5Zhang D,Fan D.Multidrug resistance in gastric cancer:recent research advances and ongoing therapeutic challenges.Expert Rev Anticancer Ther,2007,7:1369-1378.
  • 6Peng CW,Li Y,Yang GL,et al.Postoperative recurrence in gastric cancer:Analysis of 59 cases.Hepatogaatroenterlogy,2009,in press.
  • 7Kodera Y,Ito S,Monchizuki Y,et al.A phase Ⅱ study of radical surgery followed by postoperative chemotherapy with S-1 for gastric carcinoma with free cancer cells in the peritoneal cavity (CCOG0301study).Eur J Surg Oncol,2009,35:1158-1163.
  • 8Sakuramoto S,Mitsuru S,Yamaguchi T,et al.Adjuwant chemotherapy for gastric cancer with S-1,an oral Fluoropyrimidine.N Engl J Med,2007,357:1810-1820.
  • 9Shi H,Lu D,Shu Y,et al.Expression of multidrug-resistance-related proteins P-glycoprotein,glutathione-S-transterases,topoisomerase-Ⅱ and Lung resistance protein in primary gastric cardiac adenocarcinoma.Cancer Invest,2008,26:344-351.
  • 10Lordick F,J(a)ger D.Current status and future of chemotherapy and biochemotherapy in gastroosophageal cancer.Gastrointest Cancer Res,2008,2:187-197.

共引文献4

同被引文献37

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部